Chris Dokomajilar, Business Development Analyst, Recombinant Capital
Chris Dokomajilar is a Business Development Analyst at Recombinant Capital (Recap) where he analyzes alliances and trends in the biotech and pharmaceutical industry. His focus areas include specific diseases and technologies, M&A, and company valuations. Recap is a consulting firm in the San Francisco Bay Area, founded in 1988, specializing in biotech and pharmaceutical alliances, alliance revenues, and company valuations with some of the largest and most detailed biotech business intelligence databases in the world. Nine databases, including Alliances, Valuations, and Clinical Trial are available at Recap.com and rDNA.com.
Prior to joining Recap, Chris worked with the University of California San Francisco researching epidemiological trends in infectious diseases with publications in scientific journals and managed international labs. Before transitioning into science, Chris held finance positions at Bank of America. Chris has bachelor’s degrees from the University of California Berkeley in Molecular and Cell Biology and in Integrative Biology.